Literature DB >> 24508673

Simple, fast and sensitive LC-MS/MS analysis for the simultaneous quantification of nicotine and 10 of its major metabolites.

Markus Piller1, Gerhard Gilch1, Gerhard Scherer1, Max Scherer2.   

Abstract

Urinary determination of nicotine metabolites provides an ideal tool for the quantitative assessment of the tobacco use-related nicotine dose, provided that the considered metabolites comprise a large share of the amount taken up. A method based on liquid chromatography-tandem mass spectrometry (LC-MS/MS) was developed for the sensitive, fast and robust analysis of nicotine and 10 major nicotine metabolites ("Nic+10"), including cotinine, trans-3'-hydroxy-cotinine, nicotine-N-glucuronide, cotinine-N-glucuronide, trans-3'-hydroxy-cotinine-O-glucuronide, nornicotine, norcotinine, nicotine-N'-oxide, cotinine-N'-oxide and 4-hydroxy-(3-pyridyl)-butanoic acid. Corresponding deuterated internal standards were spiked prior to a simple and straightforward solid phase extraction (SPE) procedure. Liquid chromatography was performed on a reversed phase C8 column and mass-specific detection was conducted in scheduled-MRM mode. The method was validated according to FDA Guidelines, showing excellent selectivity, precision, accuracy and robustness. The limits of quantification were in the range 0.2-2.3ng/ml for all analytes. The novel method was applied to human urine samples derived from 25 smoking subjects. Quantitative results were correlated against a previously used LC-MS/MS method and compared to reports from the literature. The relative molar profile of nicotine and its 10 major metabolites was in good agreement with the literature. In addition, correlation amongst the two methods was excellent for almost all analytes, whereas the accordance between both methods was moderate for hydroxy-cotinine-O-glucuronide and norcotinine. These deviations, however, could be explained. The current method allows the simultaneous determination of nicotine and its 10 major metabolites (metabolite coverage about 95% of the absorbed dose) from a small sample volume and within a reasonable amount of time. Due to its wide dynamic range, high sensitivity and high throughput capabilities, this method could serve as a powerful tool for quantifying the nicotine dose of smokers, passive smokers as well as novel tobacco and nicotine product users in clinical and epidemiological studies.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers of exposure (BoE); LC–MS/MS; Mass spectrometry; Nicotine metabolism; Urine

Mesh:

Substances:

Year:  2014        PMID: 24508673     DOI: 10.1016/j.jchromb.2014.01.025

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  10 in total

1.  A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine.

Authors:  Taraneh Taghavi; Maria Novalen; Caryn Lerman; Tony P George; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-31       Impact factor: 4.254

2.  Determination of nicotine content in teeth submitted to prophylaxis and in-office bleaching by gas chromatography-mass spectrometry (GC-MS).

Authors:  Juliana L de Geus; Flávio L Beltrame; Mei Wang; Bharathi Avula; Ikhlas A Khan; Alessandro D Loguercio; Stella Kossatz; Alessandra Reis
Journal:  Clin Oral Investig       Date:  2018-02-21       Impact factor: 3.573

3.  Urine Metabolites for Estimating Daily Intake of Nicotine From Cigarette Smoking.

Authors:  Neal L Benowitz; Gideon St Helen; Natalie Nardone; Lisa Sanderson Cox; Peyton Jacob
Journal:  Nicotine Tob Res       Date:  2020-02-06       Impact factor: 4.244

4.  Simultaneous quantification of tobacco alkaloids and major phase I metabolites by LC-MS/MS in human tissue.

Authors:  Lisa Fischer; Felix Mikus; Ricarda Jantos; Gisela Skopp
Journal:  Int J Legal Med       Date:  2014-10-11       Impact factor: 2.686

5.  A randomised, controlled, two-Centre open-label study in healthy Japanese subjects to evaluate the effect on biomarkers of exposure of switching from a conventional cigarette to a tobacco heating product.

Authors:  Nathan Gale; Mike McEwan; Alison C Eldridge; Neil Sherwood; Edward Bowen; Simon McDermott; Emma Holmes; Andrew Hedge; Stuart Hossack; Oscar M Camacho; Graham Errington; John McAughey; James Murphy; Chuan Liu; Christopher J Proctor; Ian M Fearon
Journal:  BMC Public Health       Date:  2017-08-22       Impact factor: 3.295

6.  Assessment of the Exposure to NNN in the Plasma of Smokeless Tobacco Users.

Authors:  Nikola Pluym; Gerhard Scherer; Jeffery S Edmiston; Xiaohong C Jin; Mohamadi Sarkar; Max Scherer
Journal:  Chem Res Toxicol       Date:  2022-03-17       Impact factor: 3.973

7.  UHPLC-MS/MS method for the simultaneous determination of nicotine and tobacco-specific nitrosamines NNN and NNK for use in preclinical studies.

Authors:  Thomas Meikopoulos; Olga Begou; Theodoros Panagoulis; Eleni Kontogiannidou; Dimitrios G Fatouros; John H Miller; Georgios Theodoridis; Helen Gika
Journal:  Anal Bioanal Chem       Date:  2022-09-26       Impact factor: 4.478

8.  Biomarkers of Tobacco Exposure Decrease After Smokers Switch to an E-Cigarette or Nicotine Gum.

Authors:  Elaine K Round; Peter Chen; Anthony K Taylor; Eckhardt Schmidt
Journal:  Nicotine Tob Res       Date:  2019-08-19       Impact factor: 4.244

9.  Assessment of nicotine delivery and uptake in users of various tobacco/nicotine products.

Authors:  Gerhard Scherer; Janina Mütze; Nikola Pluym; Max Scherer
Journal:  Curr Res Toxicol       Date:  2022-03-11

10.  Identification of biomarkers specific to five different nicotine product user groups: Study protocol of a controlled clinical trial.

Authors:  Filip Sibul; Therese Burkhardt; Alpeshkumar Kachhadia; Fabian Pilz; Gerhard Scherer; Max Scherer; Nikola Pluym
Journal:  Contemp Clin Trials Commun       Date:  2021-06-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.